Protocol Ledger

NCT06747351 · Phase III · RECRUITING

A Study to Compare TAK-881 and HYQVIA in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

Interventional Phase III clinical trial protocol NCT06747351 sponsored by Takeda in Neurology, Psychiatry, and Pain, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-05-06 Enrollment: 59 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06747351
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)59 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06747351
Protocol FieldVerified Registry Value
NCT IdentifierNCT06747351
Consolidated Lead SponsorTakeda
Therapeutic Condition CohortNeurology, Psychiatry, and Pain
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment59 participants (ESTIMATED)
Registered Start Date2025-05-06
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Takeda across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Neurology, Psychiatry, and Pain Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI